Your Search Returned 141 tagged news reports
February 15, 2014 A 50-year-old man is evaluated for persistent heartburn and regurgitation despite taking a high-dose proton-pump inhibitor twice a day for 6 months. His symptoms have improved, but he continues to have symptoms many times a week...
Drugmaker AstraZeneca has showed it is still languishing in intensive care after patent expiries triggered an 8 per per cent fall in sales to $25.7 Despite new chief executive Pascal Soriot's recent string of acquisitions to boost Astra's pipeline,
Big pharma stocks have surged behind the market's rally, but that doesn't mean that every company in this top health care industry's performing up to healthy standards. Between the patent cliff and the latest China bribery scandal, several top
Our first story today involves Nestle, the Swiss company which is commonly associated with snacks and drinks. Yesterday, the Wall Street Journal reported that Nestle is working out a surprising deal with Cellular Dynamics International to obtain stem
Endoscopies were performed at baseline and at one, three and six months.
Just 18 months ago, Bristol-Myers Squibb expanded its diabetes franchise by paying $7 billion for Amylin Pharmaceuticals and, simultaneously, broadened a joint venture with AstraZeneca. Now, though, Bristol-Myers is selling its stake in the
Video An exterior shot of Jean Coutu store in Longueuil, Quebec, May 2, 2012 Market View A different federal judge in New York had already found in 2007 that Apotex's version of the drug infringed AstraZeneca's patent due to a thin, microscopic salt
New prescriptions and refills of the drug totaled 23.7 million. The report looks at the top 100 selling drugs in the U.S., by prescriptions and sales...On the sales side, the antipsychotic drug Abilify ( aripiprazole ) racked up the highest sales
The emptiness of AstraZeneca's drug cabinet was laid bare yesterday as a number of patent expiries including its bestselling cholesterol-buster Crestor saw the pharmaceutical giant miss City expectations on sales and profits, both of which fell for
In case you haven't heard, the pharmaceutical industry -- i.e., PhRMA -- is suing Maine, attempting to block a new law that goes into effect today. "The law, the first of its kind, sanctions the direct purchase of mail-order drugs from some foreign